SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTLT, DRQ, FUSN

NEW YORK, May 10, 2024

Catalent, Inc. (NYSE: CTLT)'s sale to Novo Holdings for $63.50 per share in cash. If you are a Catalent shareholder, click here to learn more about your rights and options.

Dril-Quip, Inc. (NYSE: DRQ)'s merger with Innovex Downhole Solutions, Inc. Upon closing of the proposed transaction, Dril-Quip stockholders would own approximately 52% of the combined company on a fully diluted basis. If you are a Dril-Quip shareholder, click here to learn more about your rights and options.

Fusion Pharmaceuticals Inc. (NASDAQ: FUSN)'s sale to AstraZeneca. Under the terms of the proposed transaction, AstraZeneca would acquire all of Fusion's outstanding shares for $21.00 per share in cash at closing plus a non-transferable contingent value right of $3.00 per share in cash payable upon the achievement of a specified regulatory milestone. If you are a Fusion shareholder, click here to learn more about your rights and options.

Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders. We would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email sadeh@halpersadeh.com or zhalper@halpersadeh.com.